AUTHORS
Katherine Shona Forsyth, PhD, Michael Vincent Gonzalez, PhD, MSc2, Joseph Zinski, PhD3, David Fajgenbaum, MD, MBA, MSc4, Melanie D Mumau, PhD5
AFFILIATIONS
1 Center for Cytokine Storm Treatment and Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 Center for Cytokine Storm Treatment and Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 Center for Cytokine Storm Treatment and Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 Center for Cytokine Storm Treatment and Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 Center for Cytokine Storm Treatment and Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
ABSTRACT
Human herpesvirus (HHV)-8-negative, idiopathic multicentric Castleman disease (iMCD) is a rare, hematologic illness involving lymphadenopathy, progressive flares of systemic inflammation, and cytokine-induced organ failure. The only FDA-approved therapy, siltuximab, blocks interleukin-6 (IL-6) and is effective in 34-50% of iMCD patients. Few treatment options for siltuximab-refractory patients exist due to a limited mechanistic understanding of iMCD. We have previously shown that iMCD patients exhibit IL-6-dependent mTOR activation and inhibiting mTOR signaling with sirolimus led to clinical improvement in a subset of patients suggesting a role for mTOR activation in iMCD pathogenesis. We also showed that IL-6-induced mTOR hyperactivation was JAK1/2 dependent. Within the lymph node (LN) tissue, however, the specific cell types integrating mTOR and IL6-JAK signaling are not known nor is their impact on iMCD histopathology.
To investigate what signaling pathways and cell types synergize with mTOR in iMCD LNs, we performed regional transcriptomics using GeoMx (Bruker) on fixed LNs from iMCD patients (n=6) and reactive controls (n=4). We profiled regions of mTOR activation using pS6+ immunofluorescence in the interfollicular space (IF), a region we previously showed to have increased pS6 staining. We found that the Hallmark IL6/JAK/STAT3 pathway was the most upregulated inflammatory pathway in these regions, suggesting that these pathways converge in iMCD LNs. We performed cell-type deconvolution and found that macrophages, monocytes, and endothelial cells were significantly enriched in iMCD compared to controls. These data suggest that in the IF region, both IL6/JAK and mTOR activation are enriched, as well as specific cell types. However, whether IL6/JAK and mTOR activation were specifically upregulated in each of these populations remained unclear.
To determine which cell types co-activate mTOR and IL6-JAK signaling, we re-analyzed single-cell RNAseq data from dissociated FFPE LN tissue (10X Genomics) from iMCD patients (n=4) and reactive controls (n=4). For each cluster, we calculated enrichment scores for mTOR and IL-6/JAK signaling and compared their differences between groups. We discovered that myeloid cells co-expressed the pathways in iMCD. Further sub-clustering indicated that CD163+ macrophages exhibited significant activity in both pathways in iMCD. ICC/IF validation on iMCD (n=4) and reactive control (n=4) LN tissue sections confirmed increased CD163+ pS6+ pSTAT3+ cells in iMCD LNs. Together, these data suggest that CD163+ macrophages integrate mTOR and IL-6/JAK signaling in iMCD and may be important in disease pathogenesis.
To investigate how these integrated signaling networks affect CD163+ macrophage function, we analyzed differential gene expression in this subcluster and identified that CD5L was the most significantly up-regulated gene in iMCD. In other contexts, CD5L has been implicated in macrophage adhesion to endothelial cells and promoting angiogenesis. Therefore, we investigated whether CD5L expression, CD163+ macrophages and endothelial cells co-localized in iMCD LNs. We performed spatial transcriptomic analysis using Visium (10X Genomics) on FFPE LN tissue from iMCD patients (n=4) and reactive controls (n=4), which allows for deconvolution of voxel-level data. In the IF space, we found significantly more CD5L+ voxels in iMCD compared to controls, and within CD5L-high voxels in iMCD, CD163+ macrophages were the most enriched cell type. We discovered that in iMCD LNs CD163+ macrophages co-localized with endothelial cells, and in voxels with both cell types the Hallmark angiogenesis signature was elevated. These data suggest that mTOR- and IL-6/JAK-activated macrophages in iMCD may promote the commonly described hypervascular phenotype in iMCD.
Together, these findings reveal that CD163+ macrophages co-activate mTOR and IL6/JAK signaling in iMCD LNs. Furthermore, CD163+ macrophages in iMCD express high levels of CD5L and co-localize with endothelial cells, potentially promoting angiogenesis. Since increased vascularity is a pathophysiological hallmark of iMCD LNs, CD5L-driven macrophage/endothelial cell interactions may contribute to iMCD histopathology and promote pathogenesis. As mTOR and IL6 signaling depend on intermediary JAK signaling in iMCD, our mechanistic-driven data suggest that targeting JAK1/2 with Ruxolitinib is a reasonable therapeutic approach for treatment-refractory patients.
DISCLOSURES
Katherine Shona Forsyth, PhD: No relevant conflicts of interest to declare.